Management of Arginine Vasopressin Deficiency (Central Diabetes Insipidus) in Neonates and Infants
Hormone Research in Paediatrics · 2025
DOI: 10.1159/000547155 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Hormone Research in Paediatrics, 2025. Verfasst von Hannah Pearlstein und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA, hep37@drexel.edu. Hauptthemen laut MEDLINE: Diabetes Insipidus, Neurogenic, Deamino Arginine Vasopressin, Arginine Vasopressin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background: Arginine vasopressin deficiency (AVP-D), previously called central diabetes insipidus (central DI), is the inability to concentrate urine despite elevated serum osmolality (i.e., volume depletion) related to inadequate production of the posterior pituitary hormone vasopressin. Without treatment, which typically consists of fluids and pharmacologic vasopressin analogs, AVP-D can quickly lead to hypernatremia and dehydration. Management of AVP-D in neonates and infants is particularly challenging for many reasons: their inability to communicate thirst, their limited renal concentrating capacity, the obligate fluids required for nutrition that may cause hyponatremia with anti-diuretic therapy, the lack of FDA-approved formulation of vasopressin analog in this age, the potential need for growth-related adjustments in nutrition, fluids, and vasopressin analogs, and a limited evidence base. Despite these challenges, multiple groups have reported experiences with the available pharmacologic options, including alternative formulations of desmopressin (buccal, standard oral tablet, orally disintegrating tablet [melt], subcutaneous) and thiazide diuretics. Summary: The objective of this mini-review was to provide pragmatic guidance on the options for long-term outpatient management of AVP-D in neonates and infants. Key Messages: Management of AVP-D in neonates and infants necessitates special considerations. For each affected patient and family, weighing the relative merits and drawbacks of each approach is critical to identify the most appropriate option, which may also change over time.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA, hep37@drexel.edu.
- Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- Hospital Pharmacy, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- Division of Endocrinology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Zitieren
APA
Pearlstein, H., Dayno, A., Zook, J., Crowley, J., Alter, C., Gutmark-Little, I., & McCormack, S. E. (2025). Management of Arginine Vasopressin Deficiency (Central Diabetes Insipidus) in Neonates and Infants. Hormone Research in Paediatrics. https://doi.org/10.1159/000547155
Vancouver
Pearlstein H, Dayno A, Zook J, Crowley J, Alter C, Gutmark-Little I, et al. Management of Arginine Vasopressin Deficiency (Central Diabetes Insipidus) in Neonates and Infants. Hormone Research in Paediatrics. 2025. doi:10.1159/000547155
BibTeX
@article{Pearlstein2025,
author = {Pearlstein, Hannah and Dayno, Allie and Zook, Jessica and Crowley, Julia and Alter, Craig and Gutmark-Little, Iris and McCormack, Shana E},
title = {Management of Arginine Vasopressin Deficiency (Central Diabetes Insipidus) in Neonates and Infants},
journal = {Hormone Research in Paediatrics},
year = {2025},
doi = {10.1159/000547155}
}
EUVIMED